PAI-1 modulates cell migration in a LRP1-dependent manner via β-catenin and ERK1/2.

PubWeight™: 0.86‹?›

🔗 View Article (PMID 25694133)

Published in Thromb Haemost on February 19, 2015

Authors

Nina Kozlova, Jan K Jensen, Tabughang Franklin Chi, Anatoly Samoylenko1, Thomas Kietzmann2

Author Affiliations

1: Anatoly Samoylenko, Faculty of Biochemistry and Molecular Medicine, University of Oulu, P. O.Box 3000, FI-90014 Oulu, Finland, E-mail: anatoliy.samoylenko@oulu.fi.
2: Thomas Kietzmann, Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, P. O.Box 3000, FI-90014 Oulu, Finland, Tel : +358 2 9448 7713, Email: tkietzm@gwdg.de.

Articles by these authors

Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost (2004) 1.11

Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached beta-strand 1C. J Biol Chem (2006) 1.04

Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis. FEBS J (2006) 0.97

Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1. J Biol Chem (2011) 0.96

The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol Chem (2002) 0.92

Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1. Biochem J (2003) 0.91

Hepatocyte growth factor activator inhibitor-2 prevents shedding of matriptase. Exp Cell Res (2013) 0.91

RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1. Biochemistry (2010) 0.90

Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem (2008) 0.89

Structural insight into inactivation of plasminogen activator inhibitor-1 by a small-molecule antagonist. Chem Biol (2013) 0.87

Mutational analysis of plasminogen activator inhibitor-1. Eur J Biochem (2003) 0.87

A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state. Mol Pharmacol (2008) 0.84

Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility. J Mol Biol (2011) 0.83

Elucidation of the contribution of active site and exosite interactions to affinity and specificity of peptidylic serine protease inhibitors using non-natural arginine analogs. Mol Pharmacol (2011) 0.83

Mapping of the epitope of a monoclonal antibody protecting plasminogen activator inhibitor-1 against inactivating agents. Eur J Biochem (2003) 0.82

Protein conformational change delayed by steric hindrance from an N-linked glycan. J Mol Biol (2013) 0.81

Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements. Biochemistry (2009) 0.80

The binding mechanism of a peptidic cyclic serine protease inhibitor. J Mol Biol (2011) 0.78

Increased levels of the HER1 adaptor protein Rukl/CIN85 contribute to breast cancer malignancy. Carcinogenesis (2012) 0.78

Detection of active matriptase using a biotinylated chloromethyl ketone peptide. PLoS One (2013) 0.78

Bicyclic peptide inhibitor of urokinase-type plasminogen activator: mode of action. Chembiochem (2013) 0.78

Novel modes of oestrogen receptor agonism and antagonism by hydroxylated and chlorinated biphenyls, revealed by conformation-specific peptide recognition patterns. Mol Cell Endocrinol (2008) 0.76

Urokinase-type plasminogen activator-like proteases in teleosts lack genuine receptor-binding epidermal growth factor-like domains. J Biol Chem (2012) 0.75

The N-terminal cytoplasmic region of NCBE displays features of an intrinsic disordered structure and represents a novel target for specific drug screening. Front Physiol (2013) 0.75

Resveratrol: beneficial or not? Opposite effects of resveratrol on hypoxia-dependent PAI-1 expression in tumour and primary cells. Thromb Haemost (2015) 0.75

Latency transition of plasminogen activator inhibitor type 1 is evolutionarily conserved. Thromb Haemost (2017) 0.75

The adaptor protein Ruk/CIN85 activates plasminogen activator inhibitor-1 (PAI-1) expression via hypoxia-inducible factor-1alpha. Thromb Haemost (2010) 0.75

Protein-encapsulated bilirubin: paving the way to a useful probe for singlet oxygen. Photochem Photobiol Sci (2015) 0.75

The crystal structure of a multidomain protease inhibitor (HAI-1) reveals the mechanism of its auto-inhibition. J Biol Chem (2017) 0.75